BG Medicine, Inc.  

(Public, NASDAQ:BGMD)   Watch this stock  
Find more results for BGMD
0.680
-0.019 (-2.72%)
Real-time:   1:49PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.67 - 0.71
52 week 0.27 - 1.24
Open 0.71
Vol / Avg. 50,912.00/163,908.00
Mkt cap 23.53M
P/E     -
Div/yield     -
EPS -0.20
Shares 34.65M
Beta 1.27
Inst. own 26%
Aug 12, 2015
Q2 2015 BG Medicine Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 14, 2015
Q1 2015 BG Medicine Inc Earnings Release
May 14, 2015
Q1 2015 BG Medicine Inc Earnings Call
Mar 31, 2015
Q4 2014 BG Medicine Inc Earnings Release
Mar 31, 2015
Q4 2014 BG Medicine Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -308.47% -289.34%
Operating margin -287.41% -264.15%
EBITD margin - -259.45%
Return on average assets -138.30% -110.60%
Return on average equity - -
Employees 7 -
CDP Score - -

Address

SUITE 210, 880 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-781-8901199 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BG Medicine, Inc. is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. The Company’s BGM Galectin-3 Test is its first United States Food and Drug Administration, or FDA, cleared and CE Marked diagnostic product, available as a blood test in the United States and the European Union. The Company’s BGM Galectin-3 Test was included in the 2013 American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure. The Company markets and sells BGM Galectin-3 Test kits to clinical laboratories, hospitals, and health care providers. BG Medicine N.V. is the Company’s subsidiary.

Officers and directors

Paul R. Sohmer M.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Stephen P. Hall Chief Financial Officer, Executive Vice President, Treasurer
Age: 63
Bio & Compensation  - Reuters
Aram Adourian Ph.D. Senior Vice President, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Harry W. Wilcox III Director
Age: 60
Bio & Compensation  - Reuters
Noubar B. Afeyan Independent Director
Age: 52
Bio & Compensation  - Reuters
Harrison M. Bains Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters
Timothy Harris Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Stelios B. Papadopoulos Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters